Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7552W HIGH $15.02
Volume
8.52 M
Value Traded
427.59 M
Short % Float
13.38%
-12.52%Week
+8.78%1 Month
+76.76%3 Month
+239.55%6 Month
-83.34%5 Year
-91.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.69 B
EPS (TTM)
-0.51
P/E Ratio
-
Ent. Value
3.15 B
Total Shares
306.66 M
Float Shares
253.59 M
Insiders
21.74%
Institutions
36.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ABCL Catalyst Timeline
Dated clinical, regulatory and corporate events for AbCellera Biologics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AbCellera Biologics Inc.
72Total events
4Upcoming
19Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Topline ReadoutABCL635Clinical Data
Top-line clinical results for both Phase 1 and Phase 2 anticipated
vasomotor symptoms due to menopausesource ↗
▲Interim AnalysisABCL635Trial
Positive interim Phase 1 data for ABCL635 SAD part
moderate-to-severe vasomotor symptoms (VMS) associated with menopausesource ↗
◆Oral PresentationPresentation
AbCellera to present at investor conferences in May and June 2026
◆Oral PresentationPresentation
AbCellera to present at investor conferences in March and April 2026
▲First Patient DosedABCL635Trial
First patients dosed in Phase 2 portion of Phase 1/2 trial of ABCL635
vasomotor symptoms due to menopausesource ↗
▲Trial InitiationABCL635Trial
Phase 2 study initiated
moderate-to-severe vasomotor symptoms (VMS) associated with menopausesource ↗
▲First Patient DosedABCL635Trial
First patient dosed in Phase 1
moderate-to-severe vasomotor symptoms (VMS) associated with menopausesource ↗
◆Timing GuidancebebtelovimabPresentation
Option for additional 350,000 doses to be exercised by September 14, 2022
COVID-19source ↗
●Supply DisruptionbebtelovimabCMC / Inspection
Existing supply expected to meet demand through late August 2022
COVID-19source ↗
●Supply DisruptionbebtelovimabCMC / Inspection
Option for additional 500,000 doses by July 31, 2022
COVID-19source ↗
▲Partnership / LicensebebtelovimabCorporate
Lilly modified purchase agreement with U.S. government for additional 150,000 doses of bebtelovimab
COVID-19source ↗
●Supply DisruptionbebtelovimabCMC / Inspection
U.S. government purchase agreement for up to 600,000 doses by March 31, 2022
COVID-19source ↗
▲Emergency Use AuthorizationbebtelovimabFDA Decision
FDA Emergency Use Authorization for bebtelovimab
mild-to-moderate COVID-19source ↗
▲Emergency Use AuthorizationbebtelovimabFDA Decision
Bebtelovimab EUA and continued use
COVID-19source ↗
▲Supply DisruptionbamlanivimabCMC / Inspection
Lilly to supply 614,000 additional doses of bamlanivimab with etesevimab to U.S. government
COVID-19source ↗
▲Supply DisruptionbamlanivimabCMC / Inspection
Minimum 400,000 doses of bamlanivimab with etesevimab to be supplied no later than Dec 31, 2021
COVID-19source ↗
▲EU ApprovalbamlanivimabEx-US Regulatory
EC Joint Procurement Agreement for up to 220,000 doses of bamlanivimab with etesevimab
COVID-19source ↗
▲Quarterly UpdateCorporate
AbCellera reports 138 cumulative programs under contract, 60 program starts, 4 molecules in clinic as of June 30, 2021
▲Partnership / LicenseCorporate
Expanded multi-year, multi-target antibody discovery collaboration with Gilead
Past FDA Catalysts and PDUFA Decisions
How ABCL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | ABCL635 | Phase 1/2 interim results | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$170M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 56%
Small Cap(rank 369 of 658)
Percentile Rank
AbCellera Biologics Inc. faces pipeline headwinds (34/100), with $261M risk-adjusted pipeline value, led by ABCL575 in Healthy Volunteers (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABCL575 Monoclonal antibodyNCT07108894 | Healthy Volunteers | Phase 1 | ACTIVE NOT_RECRUITING | 40 | Apr 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABCL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ABCL635 | vasomotor symptoms associated with menopause | Phase 1 | 2026-05-12 | robust NK3R target engagement; well-tolerated in healthy volunteers; doses ranging from 30 mg to 900 mg; multiple once monthly doses ranging from 300 mg to 600 mgRead More | AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hayden Michael RDirector | Buy | 53,613 1,373,397 held | $10.64 | 08/24/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABCL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 1.3 % (116.7 %) | 259.14 M | 33.01 M | 9.04% ( 2.74 M) |
ABCL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABCL ranks across every disease it competes in
Competitive Position is a premium feature
See how ABCL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABCL News
ABCL▼ -5.1%today
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
AbCellera announced a poster presentation of Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting. The presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy data. ABCL635 is designed to treat moderate-to-severe vasomotor symptoms associated with menopause, targeting NK3R. The meeting will take place from October 20 to 24 in San Diego, California.
Read more →ABCLAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
AbCellera will announce its third quarter 2026 financial results on November 9, 2026, followed by an earnings conference call. The call will be accessible via a live audio webcast, with a replay available afterward. AbCellera is a clinical-stage biotechnology firm dedicated to developing antibody-based therapies across various health sectors.
Read more →ABCL▲ +9.1%on this news
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
AbCellera has announced an upcoming oral presentation of Phase 2 data for its investigational drug ABCL635 at the IMS World Congress on Menopause 2026. The presentation will focus on the efficacy and safety of ABCL635 in treating moderate-to-severe vasomotor symptoms in postmenopausal women. This marks a significant step in AbCellera's development of innovative treatments for women's health.
Read more →ABCLAbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
AbCellera has announced its participation in the Cantor Global Healthcare Conference scheduled for September 9, 2026. The presentation will be accessible via a live audio webcast, with a replay available afterward. The company specializes in developing first-in-class antibody-based therapies across various medical fields.
Read more →ABCL▲ +5.9%on this news
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
AbCellera Biologics Inc. has announced the pricing of its oversubscribed public offering, selling 17,435,897 common shares at $9.75 each, along with pre-funded warrants. The offering is expected to generate around $200 million in gross proceeds, which will be used for research, development, and general corporate purposes. The closing is anticipated on August 14, 2026, pending customary conditions.
Read more →ABCL▲ +6.1%on this newsshared move
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
AbCellera Biologics Inc. has announced a proposed public offering of $200 million in common shares and pre-funded warrants. The proceeds will support the research and development of its internal pipeline, including its lead clinical program, ABCL635. The offering is contingent on market conditions, and details will be filed with the SEC.
Read more →ABCL▲ +34.8%on this news· ran to +58% by day 3shared move
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
AbCellera announced positive top-line results from the Phase 2 trial of ABCL635, a treatment for moderate-to-severe vasomotor symptoms due to menopause. The trial showed significant reductions in both frequency and severity of symptoms after a single dose. Additionally, ABCL635 was well-tolerated with improvements in sleep and patient satisfaction. The company plans to advance to Phase 3 trials.
Read more →ABCL▲ +34.8%on this news· ran to +58% by day 3shared move
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
AbCellera is set to announce top-line results from its Phase 2 trial of ABCL635, aimed at treating moderate-to-severe vasomotor symptoms due to menopause, on August 10, 2026. The trial involves approximately 80 postmenopausal women and is designed to assess the drug's efficacy in reducing symptom frequency and severity. An investor conference call will follow the announcement.
Read more →ABCL▲ +10.3%on this news· ran to +65% by day 3shared move
AbCellera Reports Q2 2026 Business Results
AbCellera reported its Q2 2026 financial results, highlighting the completion of enrollment for the Phase 2 study of ABCL635 and new collaborations with Jazz and Vertex. The company expects to announce top-line data from the Phase 2 trial in August 2026. Despite a significant net loss of $55.4 million, AbCellera maintains a strong liquidity position with over $675 million available.
Read more →ABCLAbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
AbCellera has announced a collaboration with Vertex Pharmaceuticals to develop multispecific T-cell engagers aimed at treating autoimmune diseases and other conditions. Under the agreement, AbCellera will utilize its TCE platform for early development, while Vertex will fund research and have commercialization rights. The deal includes an upfront payment of $28 million and potential milestone payments.
Read more →ABCL▼ -7.7%on this news
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
AbCellera will announce its second quarter 2026 financial results on August 5, 2026. The company will also hold an earnings conference call at 2:00 p.m. Pacific Time. Investors can access a live audio webcast through the company's Investor Relations website, with a replay available afterward.
Read more →ABCLAbCellera Appoints Dr. Lynn Seely to its Board of Directors
AbCellera has appointed Dr. Lynn Seely to its Board of Directors as an independent director. Dr. Seely brings extensive experience in biopharmaceuticals, having previously served as CEO at Lyell Immunopharma and Myovant Sciences. Her expertise in developing innovative therapies is expected to support AbCellera's mission of advancing antibody-based medicines.
Read more →ABCL▼ -5.7%on this news· ran to -22% by day 3
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
AbCellera reported positive interim results from the Phase 1 clinical trial of ABCL635, an antibody targeting NK3R for treating vasomotor symptoms associated with menopause. The data indicated robust target engagement and good tolerability among participants. The company plans to advance ABCL635 into Phase 2 trials, with results expected in Q3 2026. Additionally, AbCellera maintains a strong financial position with significant liquidity.
Read more →ABCL▲ +8.7%on this newsshared move
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
AbCellera Biologics Inc. announced its participation in upcoming investor conferences scheduled for May and June 2026. The company will provide live audio webcasts of its presentations, which will also be available for replay afterward. AbCellera specializes in developing first-in-class antibody-based therapies across various medical fields.
Read more →ABCLAbCellera Reports Full Year 2025 Business Results
AbCellera reported strong financial results for the full year 2025, highlighting its transition to a clinical-stage biotech company. The company ended the year with about $700 million in liquidity and advanced 19 molecules into clinical stages. The CEO emphasized the potential of their growing pipeline and upcoming clinical readouts.
Read more →ABCL▼ -6.1%on this news
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
AbCellera has announced its participation in upcoming investor conferences scheduled for March and April 2026. The company will provide live audio webcasts of its presentations, which will also be available for replay afterward. AbCellera specializes in developing antibody-based therapies across various therapeutic areas.
Read more →ABCL▼ -8.6%on this news
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
AbCellera Biologics Inc. will announce its full year 2025 financial results on February 24, 2026. The announcement will be followed by an earnings conference call at 2:00 p.m. PT. Investors can access a live audio webcast of the call on the company's Investor Relations website, with a replay available afterward.
Read more →ABCL▼ -5.5%on this news
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
AbCellera has initiated the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, a potential first-in-class treatment for vasomotor symptoms related to menopause. Following a positive interim review from Phase 1, the trial will assess the drug's efficacy in 80 postmenopausal women. Results are anticipated in Q3 2026.
Read more →ABCL▼ -7.3%on this news
AbCellera Reports Full Year 2022 Business Results 02/21/2023 Total revenue of $485 million, compared to $375 million in FY 2021 Total cumulative partnered program starts of 101, with 23 new starts in the yea
AbCellera has reported strong financial results for the year 2022, with total revenue reaching $485 million, a significant increase compared to $375 million in 2021. The company marked a 29% rise in partnered program starts and advanced a total of eight molecules into clinical trials. Despite the positive growth, AbCellera faced a net loss of $29.9 million in the fourth quarter, partly due to issues with royalties following the suspension of bebtelovimab's EUA. Overall, AbCellera sees itself at an inflection point with an expectation to deliver more clinical candidates in the future.
Read more →ABCLAbCellera Reports Q3 2022 Business Results 11/08/2022 Total revenue of $101 million, compared to $6 million in Q3 2021 Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021
AbCellera Reports Q3 2022 Business Results VANCOUVER, British Columbia, November 8, 2022 -- AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2022.
Read more →About AbCellera Biologics Inc.
Headquarters150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6
Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next ABCL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime